Thomas Reynolds

Tom Reynolds is the President of NEXT Molecular Analytics. In his previous professional positions, Reynolds was a co-founder of Commonwealth Biotechnologies, Inc, the predecessor company to NEXT Molecular Analytics, founded in 1992, and continuously served as its Executive Vice President, Director, and Secretary. Reynolds helped take CBI public in 1997, with an IPO and listing on NASDAQ. In 2009 Reynolds and Dr. Harris spun out U.S based operations of CBI into a private company, AIBioTech, LLC. Expertise in clinical molecular diagnostics and genetics, woman's health testing, next generation sequencing and personal medicine related technologies, as well as operation of BSL-3 labs. Subject matter expert in biodefense/bio-crime and human DNA forensics areas.

From 1987 until 1997, Reynolds was in the Department of Microbiology Biology and Immunology at Virginia Commonwealth University where he served as Manager of the Nucleic Acids Core Laboratory as part of the Massey Cancer Center. Reynolds is a co-inventor of U.S patents, and co-author of more than 45 peer reviewed journal articles and book chapters, in the research area of molecular genetics.